AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
14 November 2023 - 4:00PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) today announced the
publication of results from the Phase 1 study at Roswell Park
Comprehensive Cancer Center in patients with metastatic
triple-negative breast cancer using chemokine modulation therapy,
including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also
known as rintatolimod), interferon α-2b and celecoxib, followed by
pembrolizumab. The data were published in a manuscript titled,
“Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer
Patients Reprograms Local Tumor Microenvironment for Selective CTL
Influx,” in The Journal for ImmunoTherapy of Cancer.
The pilot study evaluated the safety of systemic
CKM composed of intravenous rintatolimod (Ampligen; selective TLR3
ligand), interferon α-2b and celecoxib, and the combination’s
ability to promote local CTL influx to mTNBC lesions. Principal
investigator and first author Shipra Gandhi, MD, of the Department
of Medicine at Roswell Park, led the study under the scientific
leadership of Pawel Kalinski, MD, PhD, senior author of the paper,
Chair of Immunology and Senior Vice President for Team Science at
Roswell Park. For more information about the study, please visit
ClinicalTrials.gov: NCT03599453.
For more information, please visit Roswell
Park’s website to read its press release titled “Novel
Immunotherapy Approach at Roswell Park Shows Promise in Metastatic
Triple-Negative Breast Cancer.”
About Roswell Park Comprehensive Cancer
CenterFrom the world’s first chemotherapy research to the
PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer
Center generates innovations that shape how cancer is detected,
treated and prevented worldwide. Driven to eliminate cancer’s grip
on humanity, the Roswell Park team of 4,000 makes
compassionate, patient-centered cancer care and services accessible
across New York State and beyond. Founded in 1898, Roswell
Park was among the first three cancer centers nationwide to become
a National Cancer Institute-designated comprehensive cancer center
and is the only one to hold this designation in Upstate New York.
To learn more about Roswell Park Comprehensive Cancer Center and
the Roswell Park Care Network, visit www.roswellpark.org,
call 1-800-ROSWELL (1-800-767-9355) or email
ASKRoswell@RoswellPark.org.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn,
and Facebook.Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. Among other things, for those statements, the
Company claims the protection of safe harbor for forward-looking
statements contained in the PSLRA. The Company does not undertake
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024